In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Alkermes (ALKS – Research Report), with a price ...
An RCT suggests transcranial alternating current stimulation may be an effective treatment for major depression, but outside ...
In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Alkermes (ALKS – Research Report), with a price target of $29.00. Jason Gerberry has given ...
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the ...
Alkermes (ALKS) reported $350.37 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 21.8%. EPS of $0.44 for the same period compares to $0.01 a year ago.The ...
Alkermes (ALKS) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.01 per share a year ago. These figures are ...
"The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company. During the quarter, we continued to advance our strategic priorities acros ...
The Wilmington-Clinton County Chamber of Commerce’s 2024 Annual Meeting, a hallmark event for local businesses and community ...
Q1 earnings growth expectations have sharply declined more than usual as we enter earnings season. Over the past three months, Q1 growth projections have been adjusted downward by 21.5 percentage ...
DUBLIN — DUBLIN — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based company said it had ...
Six fast-growing startups have been selected to receive a $100,000 investment each and will participate in the 12-week ...
Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the ...